文献速递泌尿男性生殖肿瘤

前列腺癌中微卫星不稳定的患病率及免疫检查点阻断治疗反应分析

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
PubMed 文献 · JAMA Oncol · 2019-01-01

该病例系列研究前瞻性分析1346例前列腺癌患者的1551份肿瘤标本,其中1033例可评估微卫星不稳定性(MSI),32例(3.1%)为MSI-H/dMMR。11例MSI-H/dMMR去势抵抗性前列腺癌患者接受抗PD-1/PD-L1治疗,6例(54.5%)前列腺特异性抗原下降超过50%,4例有影像学反应。

要点

  • 1033例可评估患者中32例(3.1%)为MSI-H/dMMR前列腺癌。
  • 11例MSI-H/dMMR去势抵抗性前列腺癌接受抗PD-1/PD-L1治疗,6例(54.5%)PSA下降>50%。
  • 32例MSI-H/dMMR患者中7例(21.9%)携带Lynch综合征相关基因致病性胚系突变。

核心结论

  • MSI-H/dMMR分子表型在前列腺癌中不常见但具有治疗意义,且可在疾病演进过程中体细胞获得。
  • 鉴于抗PD-1/PD-L1治疗可能带来持久反应,这些发现支持对所有晚期前列腺癌患者进行前瞻性肿瘤测序以筛查MSI-H/dMMR。
  • 由于并非所有MSI-H/dMMR表型患者均应答,需进一步研究探索耐药机制。

研究设计与样本

  • 病例系列研究,前瞻性分析2015年1月1日至2018年1月31日在纪念斯隆凯特琳癌症中心接受治疗的1346例前列腺癌患者的1551份肿瘤标本,采用靶向测序检测。
  • 患者诊断为前列腺癌,在计划肿瘤活检或存档组织可用时同意进行肿瘤分子分析;随访至2018年5月31日报告临床结局。
  • 1033例肿瘤质量满足MSIsensor分析的患者(平均[SD]年龄65.6[9.3]岁)纳入分析。

主要发现

  • 1033例可评估患者中32例(3.1%)为MSI-H/dMMR前列腺癌;23例(2.2%)MSIsensor评分高,另9例评分不确定但存在dMMR证据。
  • 32例MSI-H/dMMR患者中7例(21.9%)携带Lynch综合征相关基因的致病性胚系突变。
  • 6例患者有超过1个肿瘤 analyzed,其中2例在疾病后期出现获得性MSI-H表型。
  • 11例MSI-H/dMMR去势抵抗性前列腺癌患者接受抗PD-1/PD-L1治疗,6例(54.5%)前列腺特异性抗原下降超过50%,其中4例有影像学反应。
  • 截至2018年5月,6例应答者中5例(占全部11例的45.5%)仍在接受治疗,最长持续89周。

关键数值与推荐

  • MSI-H/dMMR前列腺癌患病率:1033例中32例(3.1%)。
  • MSIsensor高分肿瘤:1033例中23例(2.2%)。
  • Lynch综合征相关基因致病性胚系突变:32例MSI-H/dMMR患者中7例(21.9%)。
  • 抗PD-1/PD-L1治疗PSA下降>50%:11例中6例(54.5%)。
  • 持续治疗:6例应答者中5例(全部11例的45.5%)仍在治疗,最长89周。

临床怎么用

  • 作者认为,这些发现支持对所有晚期前列腺癌患者进行前瞻性肿瘤测序以筛查MSI-H/dMMR。
  • 作者指出,由于并非所有MSI-H/dMMR表型患者均应答,需进一步研究探索耐药机制。

局限性

  • 由于并非所有MSI-H/dMMR表型患者均应答,需进一步研究探索耐药机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab is approved by the US Food and Drug Administration for the treatment of microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors, but the prevalence of MSI-H/dMMR prostate cancer and the clinical utility of immune checkpoint blockade in this disease subset are unknown. OBJECTIVE: To define the prevalence of MSI-H/dMMR prostate cancer and the clinical benefit of anti-PD-1/programmed cell death 1 ligand 1 (PD-L1) therapy in this molecularly defined population. DESIGN, SETTING, AND PARTICIPANTS: In this case series, 1551 tumors from 1346 patients with prostate cancer undergoing treatment at Memorial Sloan Kettering Cancer Center were prospectively analyzed using a targeted sequencing assay from January 1, 2015, through January 31, 2018. Patients had a diagnosis of prostate cancer and consented to tumor molecular profiling when a tumor biopsy was planned or archival tissue was available. For each patient, clinical outcomes were reported, with follow-up until May 31, 2018. MAIN OUTCOMES AND MEASURES: Tumor mutation burden and MSIsensor score, a quantitative measure of MSI, were calculated. Mutational signature analysis and immunohistochemistry for MMR protein expression were performed in select cases. RESULTS: Among the 1033 patients who had adequate tumor quality for MSIsensor analysis (mean [SD] age, 65.6 [9.3] years), 32 (3.1%) had MSI-H/dMMR prostate cancer. Twenty-three of 1033 patients (2.2%) had tumors with high MSIsensor scores, and an additional 9 had indeterminate scores with evidence of dMMR. Seven of the 32 MSI-H/dMMR patients (21.9%) had a pathogenic germline mutation in a Lynch syndrome-associated gene. Six patients had more than 1 tumor analyzed, 2 of whom displayed an acquired MSI-H phenotype later in their disease course. Eleven patients with MSI-H/dMMR castration-resistant prostate cancer received anti-PD-1/PD-L1 therapy. Six of these (54.5%) had a greater than 50% decline in prostate-specific antigen levels, 4 of whom had radiographic responses. As of May 2018, 5 of the 6 responders (5 of 11 total [45.5%]) were still on therapy for as long as 89 weeks. CONCLUSIONS AND RELEVANCE: The MSI-H/dMMR molecular phenotype is uncommon yet therapeutically meaningful in prostate cancer and can be somatically acquired during disease evolution. Given the potential for durable responses to anti-PD-1/PD-L1 therapy, these findings support the use of prospective tumor sequencing to screen all patients with advanced prostate cancer for MSI-H/dMMR. Because not all patients with the MSI-H/dMMR phenotype respond, further studies should explore mechanisms of resistance.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Abida W, Cheng ML, Armenia J, et al. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol. 2019. PMID: 30589920. doi:10.1001/jamaoncol.2018.5801

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。